ID   ROR2_HUMAN              Reviewed;         943 AA.
AC   Q01974; Q59GF5; Q5SPI5; Q9HAY7; Q9HB61;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 2.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=Tyrosine-protein kinase transmembrane receptor ROR2;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:17717073};
DE   AltName: Full=Neurotrophic tyrosine kinase, receptor-related 2;
DE   Flags: Precursor;
GN   Name=ROR2; Synonyms=NTRKR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-245.
RX   PubMed=1334494;
RA   Masiakowski P., Carroll R.D.;
RT   "A novel family of cell surface receptors with tyrosine kinase-like
RT   domain.";
RL   J. Biol. Chem. 267:26181-26190(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 33-943, AND VARIANTS ALA-245
RP   AND ILE-819.
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 34-943, AND VARIANTS ALA-245 AND
RP   ILE-819.
RX   PubMed=10700182; DOI=10.1038/73495;
RA   Oldridge M., Fortuna A.M., Maringa M., Propping P., Mansour S.,
RA   Pollitt C., DeChiara T.M., Kimble R.B., Valenzuela D.M.,
RA   Yancopoulos G.D., Wilkie A.O.M.;
RT   "Dominant mutations in ROR2, encoding an orphan receptor tyrosine
RT   kinase, cause brachydactyly type B.";
RL   Nat. Genet. 24:275-278(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 34-574, AND VARIANT ALA-245.
RX   PubMed=10986040; DOI=10.1086/303084;
RA   Schwabe G.C., Tinschert S., Buschow C., Meinecke P., Wolff G.,
RA   Gillessen-Kaesbach G., Oldridge M., Wilkie A.O.M., Koemec R.,
RA   Mundlos S.;
RT   "Distinct mutations in the receptor tyrosine kinase gene ROR2 cause
RT   brachydactyly type B.";
RL   Am. J. Hum. Genet. 67:822-831(2000).
RN   [6]
RP   PROTEIN SEQUENCE OF 465-474, SULFATION AT SER-469 AND SER-471, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=14752058; DOI=10.1074/mcp.M300140-MCP200;
RA   Medzihradszky K.F., Darula Z., Perlson E., Fainzilber M.,
RA   Chalkley R.J., Ball H., Greenbaum D., Bogyo M., Tyson D.R.,
RA   Bradshaw R.A., Burlingame A.L.;
RT   "O-sulfonation of serine and threonine: mass spectrometric detection
RT   and characterization of a new posttranslational modification in
RT   diverse proteins throughout the eukaryotes.";
RL   Mol. Cell. Proteomics 3:429-440(2004).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH YWHAB, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17717073; DOI=10.1210/me.2007-0323;
RA   Liu Y., Ross J.F., Bodine P.V.N., Billiard J.;
RT   "Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-
RT   3(beta) phosphorylation and promotes osteoblast differentiation and
RT   bone formation.";
RL   Mol. Endocrinol. 21:3050-3061(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [9]
RP   FUNCTION, LACK OF CATALYTIC ACTIVITY, AND MUTAGENESIS OF ASP-482.
RX   PubMed=25029443; DOI=10.1371/journal.pone.0102695;
RA   Bainbridge T.W., DeAlmeida V.I., Izrael-Tomasevic A., Chalouni C.,
RA   Pan B., Goldsmith J., Schoen A.P., Quinones G.A., Kelly R., Lill J.R.,
RA   Sandoval W., Costa M., Polakis P., Arnott D., Rubinfeld B.,
RA   Ernst J.A.;
RT   "Evolutionary divergence in the catalytic activity of the CAM-1, ROR1
RT   and ROR2 kinase domains.";
RL   PLoS ONE 9:E102695-E102695(2014).
RN   [10]
RP   VARIANTS RRS CYS-184; TRP-189; TRP-366 AND LYS-620.
RX   PubMed=10932186; DOI=10.1038/78107;
RA   Afzal A.R., Rajab A., Fenske C.D., Oldridge M., Elanko N.,
RA   Ternes-Pereira E., Tueysuez B., Murday V.A., Patton M.A.,
RA   Wilkie A.O.M., Jeffery S.;
RT   "Recessive Robinow syndrome, allelic to dominant brachydactyly type B,
RT   is caused by mutation of ROR2.";
RL   Nat. Genet. 25:419-422(2000).
RN   [11]
RP   VARIANT RRS TYR-182.
RX   PubMed=10932187; DOI=10.1038/78113;
RA   van Bokhoven H., Celli J., Kayserili H., van Beusekom E., Balci S.,
RA   Brussel W., Skovby F., Kerr B., Percin E.F., Akarsu N., Brunner H.G.;
RT   "Mutation of the gene encoding the ROR2 tyrosine kinase causes
RT   autosomal recessive Robinow syndrome.";
RL   Nat. Genet. 25:423-426(2000).
RN   [12]
RP   ERRATUM.
RX   PubMed=11062486; DOI=10.1038/81722;
RA   van Bokhoven H., Celli J., Kayserili H., van Beusekom E., Balci S.,
RA   Brussel W., Skovby F., Kerr B., Percin E.F., Akarsu N., Brunner H.G.;
RL   Nat. Genet. 26:383-383(2000).
RN   [13]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-244; ALA-245; ASP-349; ALA-490;
RP   GLN-530; MET-542; SER-548; LEU-557; ASN-644; ASN-672; ARG-695;
RP   CYS-738; LEU-762; ILE-819 AND GLU-935.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase receptor which may be involved
CC       in the early formation of the chondrocytes. It seems to be
CC       required for cartilage and growth plate development (By
CC       similarity). Phosphorylates YWHAB, leading to induction of
CC       osteogenesis and bone formation (PubMed:17717073). In contrast,
CC       has also been shown to have very little tyrosine kinase activity
CC       in vitro. May act as a receptor for wnt ligand WNT5A which may
CC       result in the inhibition of WNT3A-mediated signaling
CC       (PubMed:25029443). {ECO:0000250|UniProtKB:Q9Z138,
CC       ECO:0000269|PubMed:17717073, ECO:0000269|PubMed:25029443}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:17717073}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:17717073};
CC   -!- SUBUNIT: Homodimer; promotes osteogenesis. Binds YWHAB
CC       (PubMed:17717073). Interacts with WTIP (By similarity).
CC       {ECO:0000250|UniProtKB:Q9Z138, ECO:0000269|PubMed:17717073}.
CC   -!- INTERACTION:
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-6422642, EBI-352572;
CC       P86480:PRR20D; NbExp=4; IntAct=EBI-6422642, EBI-12754095;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Single-pass
CC       type I membrane protein {ECO:0000250}.
CC   -!- DEVELOPMENTAL STAGE: Expressed at high levels during early
CC       embryonic development. The expression levels drop strongly around
CC       day 16 and there are only very low levels in adult tissues.
CC   -!- DISEASE: Brachydactyly B1 (BDB1) [MIM:113000]: A form of
CC       brachydactyly. Brachydactyly defines a group of inherited
CC       malformations characterized by shortening of the digits due to
CC       abnormal development of the phalanges and/or the metacarpals. In
CC       brachydactyly type B1 the middle phalanges are short but in
CC       addition the terminal phalanges are rudimentary or absent. Both
CC       fingers and toes are affected. The thumbs and big toes are usually
CC       deformed. Symphalangism is also a feature. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Robinow syndrome autosomal recessive (RRS) [MIM:268310]:
CC       A recessive form of Robinow syndrome, a disease characterized by
CC       short-limb dwarfism, costovertebral segmentation defects and
CC       abnormalities of the head, face and external genitalia. The
CC       clinical signs are generally far more severe in recessive cases,
CC       particularly skeletal abnormalities. All patients with the
CC       recessive form suffer from vertebral segmentation abnormalities,
CC       resulting in scoliosis and chest deformities. Rib fusions are
CC       considered to be characteristic of the autosomal recessive form.
CC       Patients can also present brachydactyly, with extensive
CC       aplasia/hypoplasia of the phalanges and metacarpals/metatarsals,
CC       and brachy-syn-polydactyly of the hands and oligodactyly of the
CC       feet. {ECO:0000269|PubMed:10932186, ECO:0000269|PubMed:10932187}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. ROR subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- CAUTION: The catalytic activity of the kinase domain is
CC       controversial. {ECO:0000269|PubMed:17717073,
CC       ECO:0000269|PubMed:25029443}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92391.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ROR2ID43476ch9q22.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M97639; AAA60276.1; -; mRNA.
DR   EMBL; AL391219; CAH70208.1; -; Genomic_DNA.
DR   EMBL; AL928802; CAH70208.1; JOINED; Genomic_DNA.
DR   EMBL; AL583841; CAH70208.1; JOINED; Genomic_DNA.
DR   EMBL; AL928802; CAI17303.1; -; Genomic_DNA.
DR   EMBL; AL391219; CAI17303.1; JOINED; Genomic_DNA.
DR   EMBL; AL583841; CAI17303.1; JOINED; Genomic_DNA.
DR   EMBL; AL583841; CAI15694.1; -; Genomic_DNA.
DR   EMBL; AL391219; CAI15694.1; JOINED; Genomic_DNA.
DR   EMBL; AL928802; CAI15694.1; JOINED; Genomic_DNA.
DR   EMBL; AB209154; BAD92391.1; ALT_INIT; mRNA.
DR   EMBL; AH009681; AAG01184.2; -; Genomic_DNA.
DR   EMBL; AH010002; AAG33132.1; -; Genomic_DNA.
DR   CCDS; CCDS6691.1; -.
DR   PIR; B45082; B45082.
DR   RefSeq; NP_001305133.1; NM_001318204.1.
DR   RefSeq; NP_004551.2; NM_004560.3.
DR   UniGene; Hs.644776; -.
DR   UniGene; Hs.98255; -.
DR   PDB; 3ZZW; X-ray; 2.90 A; A/B=464-751.
DR   PDB; 4GT4; X-ray; 2.41 A; A/B=452-753.
DR   PDBsum; 3ZZW; -.
DR   PDBsum; 4GT4; -.
DR   ProteinModelPortal; Q01974; -.
DR   SMR; Q01974; -.
DR   BioGrid; 110974; 18.
DR   IntAct; Q01974; 25.
DR   STRING; 9606.ENSP00000364860; -.
DR   ChEMBL; CHEMBL2375201; -.
DR   iPTMnet; Q01974; -.
DR   PhosphoSitePlus; Q01974; -.
DR   BioMuta; ROR2; -.
DR   DMDM; 90110767; -.
DR   EPD; Q01974; -.
DR   MaxQB; Q01974; -.
DR   PaxDb; Q01974; -.
DR   PeptideAtlas; Q01974; -.
DR   PRIDE; Q01974; -.
DR   Ensembl; ENST00000375708; ENSP00000364860; ENSG00000169071.
DR   GeneID; 4920; -.
DR   KEGG; hsa:4920; -.
DR   UCSC; uc004arj.3; human.
DR   CTD; 4920; -.
DR   DisGeNET; 4920; -.
DR   GeneCards; ROR2; -.
DR   GeneReviews; ROR2; -.
DR   H-InvDB; HIX0034840; -.
DR   HGNC; HGNC:10257; ROR2.
DR   HPA; HPA021868; -.
DR   MalaCards; ROR2; -.
DR   MIM; 113000; phenotype.
DR   MIM; 268310; phenotype.
DR   MIM; 602337; gene.
DR   neXtProt; NX_Q01974; -.
DR   OpenTargets; ENSG00000169071; -.
DR   Orphanet; 1507; Autosomal recessive Robinow syndrome.
DR   Orphanet; 93383; Brachydactyly type B.
DR   PharmGKB; PA34629; -.
DR   eggNOG; KOG1026; Eukaryota.
DR   eggNOG; ENOG410YGKQ; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOGENOM; HOG000049104; -.
DR   HOVERGEN; HBG017736; -.
DR   InParanoid; Q01974; -.
DR   KO; K05123; -.
DR   OMA; FIPMKGQ; -.
DR   OrthoDB; EOG091G02W3; -.
DR   PhylomeDB; Q01974; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-4086400; PCP/CE pathway.
DR   Reactome; R-HSA-5140745; WNT5A-dependent internalization of FZD2, FZD5 and ROR2.
DR   SignaLink; Q01974; -.
DR   SIGNOR; Q01974; -.
DR   GeneWiki; ROR2; -.
DR   GenomeRNAi; 4920; -.
DR   PRO; PR:Q01974; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000169071; -.
DR   CleanEx; HS_ROR2; -.
DR   ExpressionAtlas; Q01974; baseline and differential.
DR   Genevisible; Q01974; HS.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005874; C:microtubule; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:1904929; F:coreceptor activity involved in Wnt signaling pathway, planar cell polarity pathway; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0005109; F:frizzled binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0017147; F:Wnt-protein binding; IPI:UniProtKB.
DR   GO; GO:0014002; P:astrocyte development; IEA:Ensembl.
DR   GO; GO:0030509; P:BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0030282; P:bone mineralization; IEA:Ensembl.
DR   GO; GO:0001502; P:cartilage condensation; IEA:Ensembl.
DR   GO; GO:0045165; P:cell fate commitment; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0030538; P:embryonic genitalia morphogenesis; IEA:Ensembl.
DR   GO; GO:0042472; P:inner ear morphogenesis; IEA:Ensembl.
DR   GO; GO:0007254; P:JNK cascade; IEA:Ensembl.
DR   GO; GO:1905517; P:macrophage migration; IEA:Ensembl.
DR   GO; GO:0030539; P:male genitalia development; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0045651; P:positive regulation of macrophage differentiation; IEA:Ensembl.
DR   GO; GO:1900020; P:positive regulation of protein kinase C activity; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0060395; P:SMAD protein signal transduction; IEA:Ensembl.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEA:Ensembl.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:InterPro.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; IEA:Ensembl.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; TAS:Reactome.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   Gene3D; 2.60.40.10; -; 1.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000001; Kringle.
DR   InterPro; IPR013806; Kringle-like.
DR   InterPro; IPR018056; Kringle_CS.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR016247; Tyr_kinase_rcpt_ROR.
DR   Pfam; PF01392; Fz; 1.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF00051; Kringle; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000624; TyrPK_TMrec_ROR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00130; KR; 1.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57440; SSF57440; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00021; KRINGLE_1; 1.
DR   PROSITE; PS50070; KRINGLE_2; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane; Complete proteome;
KW   Developmental protein; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Dwarfism; Glycoprotein; Immunoglobulin domain; Kinase;
KW   Kringle; Magnesium; Membrane; Metal-binding; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Signal; Sulfation; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Wnt signaling pathway.
FT   SIGNAL        1     33       {ECO:0000255}.
FT   CHAIN        34    943       Tyrosine-protein kinase transmembrane
FT                                receptor ROR2.
FT                                /FTId=PRO_0000024460.
FT   TOPO_DOM     34    403       Extracellular. {ECO:0000255}.
FT   TRANSMEM    404    424       Helical. {ECO:0000255}.
FT   TOPO_DOM    425    943       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       55    145       Ig-like C2-type.
FT   DOMAIN      169    303       FZ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00090}.
FT   DOMAIN      316    394       Kringle. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00121}.
FT   DOMAIN      473    746       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     479    487       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS    753    782       Ser/Thr-rich.
FT   COMPBIAS    784    857       Pro-rich.
FT   COMPBIAS    859    882       Ser/Thr-rich.
FT   ACT_SITE    615    615       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     507    507       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     469    469       Sulfoserine; partial.
FT                                {ECO:0000269|PubMed:14752058}.
FT   MOD_RES     471    471       Sulfoserine; partial.
FT                                {ECO:0000269|PubMed:14752058}.
FT   MOD_RES     646    646       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     785    785       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q9Z138}.
FT   CARBOHYD     70     70       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    188    188       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    318    318       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     83    135       {ECO:0000250}.
FT   DISULFID    174    239       {ECO:0000250}.
FT   DISULFID    182    232       {ECO:0000250}.
FT   DISULFID    223    264       {ECO:0000250}.
FT   DISULFID    252    300       {ECO:0000250}.
FT   DISULFID    256    286       {ECO:0000250}.
FT   DISULFID    316    394       {ECO:0000250}.
FT   DISULFID    337    377       {ECO:0000250}.
FT   DISULFID    365    389       {ECO:0000250}.
FT   VARIANT     182    182       C -> Y (in RRS).
FT                                {ECO:0000269|PubMed:10932187}.
FT                                /FTId=VAR_010911.
FT   VARIANT     184    184       R -> C (in RRS; dbSNP:rs121909084).
FT                                {ECO:0000269|PubMed:10932186}.
FT                                /FTId=VAR_010768.
FT   VARIANT     189    189       R -> W (in RRS; dbSNP:rs199975149).
FT                                {ECO:0000269|PubMed:10932186}.
FT                                /FTId=VAR_010769.
FT   VARIANT     244    244       R -> Q (in dbSNP:rs55737262).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041787.
FT   VARIANT     245    245       T -> A (in dbSNP:rs10820900).
FT                                {ECO:0000269|PubMed:10700182,
FT                                ECO:0000269|PubMed:10986040,
FT                                ECO:0000269|PubMed:1334494,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_010912.
FT   VARIANT     349    349       H -> D (in dbSNP:rs55983376).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041788.
FT   VARIANT     366    366       R -> W (in RRS).
FT                                {ECO:0000269|PubMed:10932186}.
FT                                /FTId=VAR_010770.
FT   VARIANT     490    490       G -> A (in dbSNP:rs56197744).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041789.
FT   VARIANT     530    530       R -> Q (in dbSNP:rs35852786).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041790.
FT   VARIANT     542    542       V -> M (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs140213020).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041791.
FT   VARIANT     548    548       P -> S (in dbSNP:rs35764413).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041792.
FT   VARIANT     557    557       S -> L (in dbSNP:rs56099091).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041793.
FT   VARIANT     620    620       N -> K (in RRS).
FT                                {ECO:0000269|PubMed:10932186}.
FT                                /FTId=VAR_010771.
FT   VARIANT     644    644       D -> N (in dbSNP:rs55798732).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041794.
FT   VARIANT     672    672       D -> N (in dbSNP:rs55651110).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041795.
FT   VARIANT     695    695       G -> R (in dbSNP:rs34431454).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041796.
FT   VARIANT     738    738       R -> C (in dbSNP:rs56231927).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041797.
FT   VARIANT     762    762       S -> L (in dbSNP:rs34491822).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041798.
FT   VARIANT     819    819       V -> I (in dbSNP:rs10761129).
FT                                {ECO:0000269|PubMed:10700182,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_010913.
FT   VARIANT     935    935       D -> E (in dbSNP:rs41277835).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041799.
FT   MUTAGEN     482    482       D->G: Slight increase in kinase activity.
FT                                {ECO:0000269|PubMed:25029443}.
FT   HELIX       470    472       {ECO:0000244|PDB:4GT4}.
FT   STRAND      473    481       {ECO:0000244|PDB:4GT4}.
FT   STRAND      486    492       {ECO:0000244|PDB:4GT4}.
FT   STRAND      502    508       {ECO:0000244|PDB:4GT4}.
FT   HELIX       518    530       {ECO:0000244|PDB:4GT4}.
FT   STRAND      539    543       {ECO:0000244|PDB:4GT4}.
FT   STRAND      545    548       {ECO:0000244|PDB:4GT4}.
FT   STRAND      550    554       {ECO:0000244|PDB:4GT4}.
FT   HELIX       561    566       {ECO:0000244|PDB:4GT4}.
FT   HELIX       589    608       {ECO:0000244|PDB:4GT4}.
FT   HELIX       618    620       {ECO:0000244|PDB:4GT4}.
FT   STRAND      621    623       {ECO:0000244|PDB:4GT4}.
FT   HELIX       625    627       {ECO:0000244|PDB:4GT4}.
FT   STRAND      629    631       {ECO:0000244|PDB:4GT4}.
FT   HELIX       639    644       {ECO:0000244|PDB:4GT4}.
FT   STRAND      648    652       {ECO:0000244|PDB:4GT4}.
FT   HELIX       656    658       {ECO:0000244|PDB:4GT4}.
FT   HELIX       661    666       {ECO:0000244|PDB:4GT4}.
FT   HELIX       671    686       {ECO:0000244|PDB:4GT4}.
FT   TURN        687    689       {ECO:0000244|PDB:4GT4}.
FT   TURN        692    695       {ECO:0000244|PDB:4GT4}.
FT   HELIX       698    706       {ECO:0000244|PDB:4GT4}.
FT   HELIX       719    728       {ECO:0000244|PDB:4GT4}.
FT   HELIX       733    735       {ECO:0000244|PDB:4GT4}.
FT   HELIX       739    747       {ECO:0000244|PDB:4GT4}.
SQ   SEQUENCE   943 AA;  104757 MW;  F926FB681A8312FE CRC64;
     MARGSALPRR PLLCIPAVWA AAALLLSVSR TSGEVEVLDP NDPLGPLDGQ DGPIPTLKGY
     FLNFLEPVNN ITIVQGQTAI LHCKVAGNPP PNVRWLKNDA PVVQEPRRII IRKTEYGSRL
     RIQDLDTTDT GYYQCVATNG MKTITATGVL FVRLGPTHSP NHNFQDDYHE DGFCQPYRGI
     ACARFIGNRT IYVDSLQMQG EIENRITAAF TMIGTSTHLS DQCSQFAIPS FCHFVFPLCD
     ARSRTPKPRE LCRDECEVLE SDLCRQEYTI ARSNPLILMR LQLPKCEALP MPESPDAANC
     MRIGIPAERL GRYHQCYNGS GMDYRGTAST TKSGHQCQPW ALQHPHSHHL SSTDFPELGG
     GHAYCRNPGG QMEGPWCFTQ NKNVRMELCD VPSCSPRDSS KMGILYILVP SIAIPLVIAC
     LFFLVCMCRN KQKASASTPQ RRQLMASPSQ DMEMPLINQH KQAKLKEISL SAVRFMEELG
     EDRFGKVYKG HLFGPAPGEQ TQAVAIKTLK DKAEGPLREE FRHEAMLRAR LQHPNVVCLL
     GVVTKDQPLS MIFSYCSHGD LHEFLVMRSP HSDVGSTDDD RTVKSALEPP DFVHLVAQIA
     AGMEYLSSHH VVHKDLATRN VLVYDKLNVK ISDLGLFREV YAADYYKLLG NSLLPIRWMA
     PEAIMYGKFS IDSDIWSYGV VLWEVFSYGL QPYCGYSNQD VVEMIRNRQV LPCPDDCPAW
     VYALMIECWN EFPSRRPRFK DIHSRLRAWG NLSNYNSSAQ TSGASNTTQT SSLSTSPVSN
     VSNARYVGPK QKAPPFPQPQ FIPMKGQIRP MVPPPQLYVP VNGYQPVPAY GAYLPNFYPV
     QIPMQMAPQQ VPPQMVPKPS SHHSGSGSTS TGYVTTAPSN TSMADRAALL SEGADDTQNA
     PEDGAQSTVQ EAEEEEEGSV PETELLGDCD TLQVDEAQVQ LEA
//
